Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory Tract Diseases AND Thoracic Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    759 result(s) found for: Respiratory Tract Diseases AND Thoracic Diseases. Displaying page 38 of 38.
    «« First « Previous 30  31  32  33  34  35  36  37  38 
    EudraCT Number: 2010-019590-15 Sponsor Protocol Number: HZA106827 Start Date*: 2010-10-26
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: HZA106827: A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhala...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019594-14 Sponsor Protocol Number: HZA106829 Start Date*: 2010-07-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in th...
    Medical condition: Persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000643-27 Sponsor Protocol Number: MK-1029-012-00 Start Date*: 2012-12-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects with Persistent Asthma
    Medical condition: Adult subjects 18 to 75 years of age with persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003070-39 Sponsor Protocol Number: CYT003-QbG1012 Start Date*: 2012-11-26
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients with Moderate to Severe Allergic Asthma not Sufficiently Controlled on Current Standard T...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014551-80 Sponsor Protocol Number: 1268.16 Start Date*: 2010-01-21
    Sponsor Name:BOEHRINGER ING.
    Full Title: Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placeb...
    Medical condition: patients with symptomatic asthma on inhaled corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    12.1 10049106 Asthma chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004932-20 Sponsor Protocol Number: 1311.14 Start Date*: 2015-06-05
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 w...
    Medical condition: Severe Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) NL (Completed) DE (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001417-16 Sponsor Protocol Number: SFA106484 Start Date*: 2007-01-03
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, double-dummy, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with flutica...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) LV (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000267-72 Sponsor Protocol Number: D3252C00002 Start Date*: 2021-09-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps ...
    Medical condition: Patient with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) HU (Trial now transitioned) FR (Completed) PL (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021093-11 Sponsor Protocol Number: 205.444 Start Date*: 2010-11-13
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) del...
    Medical condition: moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) ES (Completed) SK (Completed) IT (Prematurely Ended) DE (Completed) NO (Ongoing) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002899-25 Sponsor Protocol Number: CQVM149B2302 Start Date*: 2015-12-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, 52-week, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) DE (Completed) SK (Completed) PT (Completed) AT (Completed) HU (Completed) NL (Completed) FI (Completed) BE (Completed) ES (Completed) DK (Completed) LV (Completed) GR (Completed) FR (Completed) BG (Completed) IE (Completed) HR (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000223-20 Sponsor Protocol Number: BUS-P3-01 Start Date*: 2023-02-01
    Sponsor Name:Bellus Health, Inc.
    Full Title: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, I...
    Medical condition: Refractory or Unexplained Chronic Cough
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024006-35 Sponsor Protocol Number: C38072/3083 Start Date*: 2011-05-05
    Sponsor Name:Teva Branded Pharmaceutical Products, R&D, Inc.
    Full Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-007800-13 Sponsor Protocol Number: PIPF-012 Start Date*: 2008-06-04
    Sponsor Name:InterMune, Inc.
    Full Title: An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) FR (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003258-98 Sponsor Protocol Number: VO53.06 Start Date*: 2007-04-11
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR subling...
    Medical condition: grass pollen rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039085 Rhinitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SK (Completed) AT (Completed) DK (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001263-85 Sponsor Protocol Number: SAV006-05 Start Date*: 2021-07-19
    Sponsor Name:Savara ApS
    Full Title: A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP).
    Medical condition: Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10037316 Pulmonary alveolar proteinosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IE (Trial now transitioned) DE (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) RO (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024540-15 Sponsor Protocol Number: C38072/3085 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Stu...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) SE (Completed) CZ (Completed) GR (Completed) HU (Completed) NL (Completed) DK (Prematurely Ended) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001777-43 Sponsor Protocol Number: 205.446 Start Date*: 2012-05-15
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily i...
    Medical condition: Severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003560 Asthma NOS LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) LT (Completed) DE (Completed) BE (Completed) CZ (Completed) HU (Completed) PL (Completed) SK (Completed) RO (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015878-35 Sponsor Protocol Number: BAY63-2521/14308 Start Date*: 2010-03-22
    Sponsor Name:Bayer Healthcare AG
    Full Title: Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmo...
    Medical condition: Pacientes sintomáticos con una hipertensión pulmonar asociada a una disfunción del ventrículo izquierdo (PH-sLVD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Trial now transitioned) NL (Completed) BE (Completed) AT (Completed) FR (Completed) GB (Completed) IT (Trial now transitioned) DK (Completed) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002875-42 Sponsor Protocol Number: 1199.30 Start Date*: 2007-07-06
    Sponsor Name:Boehringer Ingelheim
    Full Title: A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...
    Medical condition: Idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) IE (Completed) ES (Completed) HU (Completed) CZ (Completed) FR (Completed) IT (Completed) PT (Completed) GR (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 30  31  32  33  34  35  36  37  38 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 10:38:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA